Aflac Incorporated

AFL · NYSE · USD

Whether Aflac Japan's record sales of Miraito, Tsumitasu and Anshin Palette can turn shrinking earned premiums into growth before rising benefit ratios erode margins.

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Japan product sales momentum

    The bull case is that three concurrent Japan product launches are rebuilding sales in a market where Aflac already holds a large, persistent in-force block.

  • U.S. group benefits growth

    Group dental, life and disability sales in the U.S. are growing fast enough to offset the shrinking traditional individual block and lift earned premiums.

  • Share repurchase capacity

    Heavy buybacks shrink the share count while strong solvency ratios leave room to keep repurchasing stock and raising the dividend.

  • Bermuda reinsurance expansion

    An expanding Bermuda reinsurance platform gives Aflac a new use of capital by assuming Japanese insurance blocks from third parties.

Bear case

  • Japan earned premium runoff

    The bear case is that Japan sales growth has not reversed the decline in earned premiums, because lapses and paid-up policies still outrun new sales.

  • Rising benefit ratios

    Benefit ratios are drifting higher in both segments as product mix shifts toward group life and disability and fewer older policies lapse.

  • U.S. traditional block decline

    The traditional U.S. individual voluntary block keeps shrinking as brokers move to group products, leaving overall U.S. premium growth short of the company's own range.

  • Earnings quality and one-offs

    Reported earnings lean on actuarial assumption updates that lift one quarter at a time, while the corporate segment now runs at a loss.

Bull and bear points

Growth & Execution

In short: Japan product launches are lifting sales sharply, while earned premiums in Japan are still shrinking.

Bull · 2

  • Three Japan products sold at once lift sales above last year

    Selling cancer, medical and savings products together widens the customer base to younger buyers and reduces reliance on any single launch.

    Q2 FY2026 call

  • Group dental, life and disability carry U.S. sales growth

    Broker-sold group products are growing at double-digit rates and pull voluntary benefits alongside them, which partly offsets the weaker agent-sold block.

    Q4 FY2025 call
Bear · 3

  • Japan sales have not yet turned earned premiums positive

    Record sales still leave the in-force shrinking, and Japan segment revenue fell 12.6% year on year in the latest quarter as lapses outran new premium.

    Q1 FY2026 call

  • U.S. premium growth guided just below its range

    Management now expects 2026 U.S. net earned premium growth just under the low end of the range, showing the shrinking agent-sold block is offsetting group gains.

    Q2 FY2026 call

  • Japan sales target language has softened since April

    In April management wanted Japan sales closer to JPY 80 billion; by August it called that figure a challenge and committed only to beating the prior year total.

    Tone shiftQ1 FY2026 → Q2 FY2026

Profitability & Financial Strength

In short: Capital return is funded from a strong balance sheet, while benefit ratios keep drifting higher.

Bull · 2

  • Buybacks cut the diluted share count by 16% over three years

    A smaller share count lifts earnings per share without needing profit growth, and Aflac has funded repurchases from holding-company cash rather than new debt.

    Q4 FY2025 call

  • Japan expense ratio falls despite domestic inflation

    Japan's expense ratio came in below last year's level even with domestic inflation near 3%, which protects segment margins while premium income shrinks.

    Q2 FY2026 call
Bear · 2

  • Japan benefit ratio now expected at the top of its range

    In April management expected to land inside the range; by August it guided to the high end, citing a change in which policies lapse and release reserves.

    Tone shiftQ1 FY2026 → Q2 FY2026

  • Reported earnings lean on actuarial assumption updates

    The third quarter of 2025 included a large gain from reserve remeasurement, so reported results ran well above the underlying earnings rate.

    Q3 FY2025 call

Market Position

In short: Aflac reaches Japan through many channels, but its agent-sold U.S. block is shrinking.

Bull · 2

  • Reinsurance ceding target raised from 10% to 30% of reserves

    In February the internal target was 10% of U.S. GAAP assets; by August it was reframed as up to 30% of FSA reserves, widening a new source of earnings.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Sales grew through every Japan distribution channel

    Agencies, Japan Post and regional banks each added sales, so growth does not depend on one partner and the products reach younger Japanese customers.

    Q4 FY2025 call
Bear · 2

  • Agent-sold individual voluntary block keeps shrinking

    Brokers increasingly sell group coverage, so Aflac's large traditional individual block is flat to negative and holds total U.S. sales growth in the low single digits.

    Q4 FY2025 call

  • A state regulator required rate cuts on some U.S. products

    Regulatory limits on supplemental pricing constrain how far Aflac can raise rates to cover higher claims, and management describes the pressure as isolated rather than resolved.

    Q1 FY2026 call